Gritstone Oncology

GRTS42

Penny Stock

$0.62arrow_drop_down1.49%-$0.00

Penny Stock

GRTS42

$0.62

arrow_drop_down1.49%-$0.00

Penny Stock

Performance History

Key Stats
Open	$0.62
Prev. Close	$0.63
EPS	-1.09
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$66.16M
PE Ratio	-

	LOW	HIGH
Day Range	0.61	0.62
52 Week Range	0.42	3.33

Ratios







EPS	-1.09

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Gritstone Oncology (GRTS)

Gritstone Oncology Inc (GRTS) is a biotechnology company that focuses on developing personalized cancer immunotherapies. The company's approach is based on the concept of treating each patient's unique tumor mutations with targeted therapies. Gritstone aims to overcome the limitations of traditional cancer treatments by harnessing the power of the immune system to recognize and eliminate cancer cells. The company's innovative platform combines genomic data, machine learning, and advanced immunology to create patient-specific therapies.

Gritstone Oncology Inc's stock price history reflects the volatile nature of the biotech industry. Since its initial public offering in 2018, the stock has experienced both significant gains and losses. Investors interested in GRTS should carefully evaluate the company's potential for future growth and the associated risks. It is important to note that biotech stocks generally carry a higher level of risk compared to other sectors.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Headquarters: EmeryVille
Employees: 233
Exchange: NASDAQ

Keep an eye on Gritstone Oncology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Gritstone Oncology 's (GRTS) price per share?

The current price per share for Gritstone Oncology (GRTS) is $0.62. The stock has seen a price change of -$0.01 recently, indicating a -1.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Gritstone Oncology (GRTS)?

For Gritstone Oncology (GRTS), the 52-week high is $3.33, which is 436.58% from the current price. The 52-week low is $0.42, the current price is 47.76% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Gritstone Oncology (GRTS) a growth stock?

Gritstone Oncology (GRTS) has shown an average price growth of 0.41% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Gritstone Oncology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Gritstone Oncology (GRTS) stock price performance year to date (YTD)?

As of the latest data, Gritstone Oncology (GRTS) has a year-to-date price change of -71.53%. Over the past month, the stock has experienced a price change of 22.82%. Over the last three months, the change has been -14.85%. Over the past six months, the figure is -77.1%. Looking at a longer horizon, the five-year price change stands at -93.64%.

help

Is Gritstone Oncology (GRTS) a profitable company?

Gritstone Oncology (GRTS) has a net income of -$138.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.33M, although specific revenue growth data is currently not available. Operating income is noted at -$154.63M. Furthermore, the EBITDA is -$129.23M.

help

What is the market capitalization of Gritstone Oncology (GRTS)?

Gritstone Oncology (GRTS) has a market capitalization of $66.16M. The average daily trading volume is 747.16K, indicating the stock's liquidity and investor engagement.

News

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GRITSTONE BIO

SECURITIES CLASS ACTION

COVID-19 VACCINE

8/4/2024

GRTS DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Gritstone bio, Inc. Investors to Secure Counsel Before Important August 6 Deadline in Securities Class Action – GRTS

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, Gritstone, Fat Brands, and Charge and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Scotts, Gritstone, Fat Brands, and Charge and Encourages Investors to Contact the Firm

DEADLINE ALERT for TDC, GRTS, PATH, NKE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

DEADLINE ALERT for TDC, GRTS, PATH, NKE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

GRITSTONE BIO

SECURITIES CLASS ACTION

COVID-19 VACCINE

7/25/2024

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Gritstone bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRTS

GRITSTONE BIO

SECURITIES CLASS ACTION

COVID-19 VACCINE

7/19/2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Gritstone bio, - GlobeNewswire